Literature DB >> 18166464

Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia.

Robert H Dworkin1, John W Gnann, Anne Louise Oaklander, Srinivasa N Raja, Kenneth E Schmader, Richard J Whitley.   

Abstract

UNLABELLED: Accurate evaluation of pain plays a critical role in identifying new interventions for the treatment and prevention of herpes zoster and postherpetic neuralgia (PHN). Different types of pain and other sensory symptoms are found in patients with herpes zoster, and these vary greatly with respect to their presence, location, duration, intensity, and quality. The results of recent studies of herpes zoster and PHN and the development of new methods for assessing neuropathic pain provide a foundation for diagnosing and assessing the pain associated with herpes zoster. We review the results of recent research to identify the essential components that must be considered in developing an evidence-based description of pain associated with herpes zoster and PHN. PERSPECTIVE: Comprehensive assessments of pain are necessary for clinical research on the epidemiology, natural history, pathophysiologic mechanisms, treatment, and prevention of pain in herpes zoster and PHN.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18166464     DOI: 10.1016/j.jpain.2007.10.008

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  61 in total

1.  The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study.

Authors:  Mélanie Drolet; Marc Brisson; Kenneth E Schmader; Myron J Levin; Robert Johnson; Michael N Oxman; David Patrick; Caty Blanchette; James A Mansi
Journal:  CMAJ       Date:  2010-10-04       Impact factor: 8.262

Review 2.  Epidemiology of neuropathic pain and its impact on quality of life.

Authors:  Blair H Smith; Nicola Torrance
Journal:  Curr Pain Headache Rep       Date:  2012-06

3.  Zoster vaccination: A new opportunity for adult immunization.

Authors:  Kevin B Laupland; David N Fisman
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

4.  Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers.

Authors:  Helen S Pentikis; Mark Matson; George Atiee; Brian Boehlecke; Jeff T Hutchins; Joseph M Patti; Geoffrey W Henson; Amy Morris
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

5.  Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: a randomized study of a single dose vs. two different two-dose schedules.

Authors:  Timo Vesikari; Roland Hardt; Hans C Rümke; Giancarlo Icardi; Jordi Montero; Stéphane Thomas; Christine Sadorge; Anne Fiquet
Journal:  Hum Vaccin Immunother       Date:  2013-01-14       Impact factor: 3.452

Review 6.  The role of sensory fiber demography in trigeminal and postherpetic neuralgias.

Authors:  A F DaSilva; M F DosSantos
Journal:  J Dent Res       Date:  2011-06-13       Impact factor: 6.116

7.  Immunogenicity and safety of ZOSTAVAX(®) approaching expiry potency in individuals aged ≥50 years.

Authors:  Robert Arnou; Anne Fiquet; Stéphane Thomas; Christine Sadorge
Journal:  Hum Vaccin       Date:  2011-10-01

8.  Impact of herpes zoster and post-herpetic neuralgia on patients' quality of life: a patient-reported outcomes survey.

Authors:  Thomas Weinke; Alexander Edte; Sonja Schmitt; Kati Lukas
Journal:  Z Gesundh Wiss       Date:  2010-03-21

Review 9.  HSV vector-mediated modification of primary nociceptor afferents: an approach to inhibit chronic pain.

Authors:  J R Goss; M S Gold; J C Glorioso
Journal:  Gene Ther       Date:  2009-04       Impact factor: 5.250

10.  Acupuncture in acute herpes zoster pain therapy (ACUZoster) - design and protocol of a randomised controlled trial.

Authors:  Johannes Fleckenstein; Sybille Kramer; Philipp Hoffrogge; Sarah Thoma; Philip M Lang; Lukas Lehmeyer; Gabriel M Schober; Florian Pfab; Johannes Ring; Peter Weisenseel; Klaus J Schotten; Ulrich Mansmann; Dominik Irnich
Journal:  BMC Complement Altern Med       Date:  2009-08-12       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.